Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) reported promising results from a midstage trial of its colorectal cancer treatment perifosine lifting the stock price 55 cents to $5.03.
Promising Results For Keryx
May 21, 2010 at 13:30 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.